Sharekhan's research report on PI Industries
Revenue/OPM of Rs. 1,395 crore/22%, up 16.5%/287 bps y-o-y met expectations but PAT of Rs. 204 crore (up 14% y-o-y) missed estimates on lower other income and a higher tax rate. CSM/domestic revenues grew by 11%/47% y-o-y to Rs. 1,114 crore/Rs. 281 crore, led by strong volume growth (9.5% y-o-y) and partial price hikes (of 7% y-o-y). Margin benefited from price hike, operating leverage and better product mix. Management guided for an 18-20% y-o-y revenue growth for FY23 and sees scope for margin improvement with ramp-up of new products recently commercialised, operating leverage and price hike for certain products. PI is actively evaluating options in pharma space for acquisition in CDMO/API side.
Outlook
We maintain a Buy on PI Industries with a revised PT of Rs. 3,300. A potential acquisition in the pharma space would improve long-term earnings growth outlook and makes us constructive on the stock. At CMP, the stock trades at 36.9x/29.6x FY23E/FY24E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!